AMGEN Inc.

NASDAQ:AMGN 4:00:00 PM EDT

229.83

-3.12 (-1.34%)

7:51:48 PM EDT: $230.96 +1.13 (+0.49%)

Products

Amgen Says Amjevita (Adalimumab-Atto), A Biosimilar To Humira (Adalimumab), Is Now Available In U.S.

Published: 01/31/2023 11:34 GMT

AMGEN Inc. (AMGN) - Amgen - Amjevita (adalimumab-atto), a Biosimilar to Humira (adalimumab), is Now Available in U.S.amgen - Amjevita is Also Available at List Price 5% Below Current Humira List Price.
Amgen - Amjevita (40 Mg) is Available at a List Price (wholesale Acquisition Cost) 55% Below Current Humira List Price.
Further Company Coverage: Amgno ((reuters.
Briefs@thomsonreuters.
Com;)).